Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Form 8.3 - Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 11th February 2026 2.

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes' completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel's FDA-approved product, LUMRYZ®, to Alkermes' commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes' entry into the sleep medicine market.

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORM A TION Name of person dealing (Note 1) State Street Global Advisors & Affiliates Company dealt in Avadel Pharmaceuticals plc Class of relevant security to which the dealings being disclosed relate (Note 2) $0.01 ordinary shares Date of dealing 10th February 2026 2.

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.